The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Findings from a Phase Ib/II trial assessing azacitidine, venetoclax & ivosidenib in IDH1-mutated AML
Akriti Jain, MD, Cleveland Clinic, Cleveland, OH, shares insights into a Phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in IDH1-mutated acute myeloid leukemia (AML). Dr Jain highlights high overall and composite response rates, exceeding those reported in previous studies, including the VIALE-A study (NCT02993523), and emphasizes that these outcomes may help to improve patient eligibility for transplant. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
